Study of HER2/neu status in Qatari women with breast carcinoma

Saudi Medical Journal

Volumn 24, Issue 8, 2003, Pages 832-836

  Rasul, Kakil I ^a   Mohammaed, Kelta ^a   Abdalla, Awidi S ^a   Chong Lopez, Augustin ^a   Ahmad, Mubarak A ^a   Al Homsi, Mohammed U ^a   Al Hassan, Asma M ^a   Al Alosi, Ahmad S ^a   Bener, Bener A ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PARAFFIN;

ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; COVARIANCE; ETHNOLOGY; FEMALE; FOLLOW UP; GENDER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PREVALENCE; QATAR; RETROSPECTIVE STUDY; SAMPLE SIZE; SURVIVAL TIME; TISSUE SECTION;

ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QATAR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141815685     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Yamauchi H, Stearns V, Hayes D. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
2. Trock BJ, Yamauchi H, Brotzman M, Stearn V, Hayes D. c-erbB-2 as a prognostic factor in breast cancer: a meta-analysis (abstract). Proc Am Soc Clin Oncol 2000; 19: 97a.
3. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J of Cancer 2001; 37: S3-10.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-182.
5. Borg A, Tandom AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA et al. HER2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332-4335.
6. Gusterson BA, Gelber RD, Goldhirch A, Price KN, Save-Soderborg J, Anbazhagan R et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-1056.
7. Hartmann LC, Ingle JN, Wold LE, Price KN, Save-Sadenborg J, Anbazhagan R. Prognostic value of c-erbB2 overexpression in axillary lymph node-positive breast cancer. Result from randomized adjuvant treatment protocol. Cancer 1994; 74: 2956-2963.
8. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326: 1756-1761.
9. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206-1219.
10. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is quote statistically significant; clinically useful? Breast Cancer Res Treat 1998; 52: 305-319.
11. Hayes DF. Do we need prognostic factors in nodal-negative breast cancer? Arbiter. Eur J Cancer 2000; 36: 302-306.
12. King CR, Kraus MH, Aaronson SA. Amplification of a novel c-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974.
13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
14. Rajeshwari R, Jannette H, Tina J, Kevin C, Minu K, Kindo D et al. Plasma e-erbB-2 levels in breast cancer patients; prognistic significance in predicting response to chemotherapy. J Clin Oncol 1998; 16: 2409-2416.
15. Ross JS, Fletcher JA. The HER2/neu oncogene in breast cancer: predictive factor, and target for for therapy. Stem Cells 1998; 16: 413-428.
16. McGann AH, Dervan PA, O Regan M, Codd MB, Gullick WJ, Tabin BM. Prognostic significance of cerbB-2 and estrogen receptor stsuts in human breast cancer. Cancer Res 1991; 51: 3296-3303.
17. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Tragani M, Darand M. The prognostic value of c-erbB-2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995; 35: 283-291.
18. Press MF, Bernstein L, Thomas PA, Maisner LF, Zhou JY, Ma Y et al. HER2/neu gene amplification characterized by flourescence in situ hybridization poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 1894-1904.
19. Birner P, Oberhuber G, Stani J, Reithofer C, Samoning H, Housemannger H et al. Evaluation of the United States Food and Drug Administration - approved Scoring and Test System for HER2 Protein Expression in Breasr Cancer. Clin Canc Res 2001; 7: 1669-1675.
20. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B et al. HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparision of Immunohistochemistry and Fluorescence In Situ Hybridization. J Clin Oncol 2001; 19: 354-363.
21. Ridolfi R, Jamehdor M, Arber J. HER2/neu testing in breast carcinoma: A combined immunohistochemistry and flourescence in situ hybridization approch. Mod Pathol 2001; 13: 866-873.
22. Vera R, Albanell J, Lirola J, Bermjo B, Sole LA, Baselga J. HER2 over expression as a predictor of survival in atrial comparing adjuvant FAC and CMF in breast cancer. Proceding Am Soc Clin Oncol 1998; 18: 71a [Abstract 265].
23. Muss HB, Thor A, Berry DA, Kute T, Liu ET, Koerner F. c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266.
24. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370.
25. Ravdin P, Green S, Albain K, Boucher V, Ingle J, Pritchard K et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone [abstract 374]. Proc Am Soc Clin Oncol 1998; 17: 97a.
26. Paik S, Bryant J, Tan-Chiu E, Yother G, Park C, Wickenham DL. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92: 1991-1998.